From: Regulation and prognostic relevance of serum ghrelin concentrations in critical illness and sepsis
Parameter | All patients | Sepsis | non-Sepsis |
---|---|---|---|
Number | 170 | 122 | 48 |
Sex (male/female) n | 111/59 | 81/41 | 30/18 |
Age median (range) (years) | 63 (18 to 86) | 64 (20 to 86) | 60 (18 to 79) |
APACHE-II score median (range) | 14 (0 to 31) | 14 (0 to 31) | 15 (0 to 31) |
SAPS2 score median (range) | 44 (0 to 80) | 45 (0 to 79) | 41 (13 to 80) |
ICU days median (range) | 8.5 (1 to 137) | 10 (1 to 137) | 6 (1 to 45) |
Hospital days median (range) | 27 (2 to 151) | 30 (2 to 151) | 14 (2 to 85) |
Death during ICU n(%) | 54 (32%) | 42 (34%) | 12 (25%) |
Death during follow-up n(%) | 88 (52%) | 64 (53%) | 24 (50%) |
30-day mortality [%] | 32% | 32% | 31% |
60-day mortality [%] | 39% | 40% | 35% |
90-day mortality [%] | 42% | 44% | 35% |
180-day mortality [%] | 45% | 48% | 38% |
1-year mortality [%] | 49% | 51% | 44% |
Mechanical ventilation n(%) | 113 (67%) | 82 (67%) | 31 (65%) |
Ventilation time median (range) [h] | 66 (1 to 2,966) | 127.5 (1 to 2,966) | 31 (1 to 755) |
pre-existing diabetes n(%) | 56 (33%) | 39 (32%) | 17 (35%) |
BMI median (range) (m²/kg) | 25.8 (14.0 to 59.5) | 26.0 (14.0 to 59.5) | 25.1 (17.5 to 53.3) |
Serum IGF-1 median (range) (μg/L) | 54 (25 to 295) | 54 (25 to 295) | 49 (25 to 165) |
Serum growth hormone median (range) (μg/L) | 1.5 (0.1 to 128.0) | 1.3 (0.1 to 128.0) | 2.0 (0.1 to 22.3) |
Serum ghrelin median (range) (pmol/L) | 18.4 (5.0 to 129.5) | 18.4 (5 to 113.8) | 18.4 (5 to 129.5) |